Lupin is currently trading at Rs. 805.20, up by 3.85 points or 0.48% from its previous closing of Rs. 801.35 on the BSE.
The scrip opened at Rs. 785.10 and has touched a high and low of Rs. 809.20 and Rs. 785.10 respectively. So far 72773 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.
Last one week high and low of the scrip stood at Rs. 867.05 and Rs. 785.00 respectively. The current market cap of the company is Rs. 36294.09 crore.
The promoters holding in the company stood at 46.97%, while Institutions and Non-Institutions held 38.07% and 14.96% respectively.
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the Post-marketing Adverse Drug Experience (PADE) inspection, indicating successful closure of the inspection.
The inspection was conducted at company’s global pharmacovigilance group DSRM (Drug Safety & Risk Management) based out of Mumbai between January 14, 2019 and January 18, 2019. The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide. The inspection closed with four observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
The post Lupin gains on receiving EIR from USFDA appeared first on Udaipur News | Udaipur Latest News | udaipur local news.
